Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge

Launched by VANDERBILT UNIVERSITY MEDICAL CENTER · Feb 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how continuous glucose monitoring (CGM) can help manage diabetes better after patients leave the hospital. The goal is to help patients understand how these monitoring systems work and to make them feel more satisfied with their diabetes care, especially when transitioning from hospital to home. The trial is looking for adults aged 18 and older who have high blood sugar levels requiring insulin during their hospital stay. Participants need to be able to use a smartphone app to track their glucose levels and must have blood sugar readings between 70-350 mg/dL prior to joining.

If you are interested in participating, you should know that you cannot have used certain glucose monitoring devices in the past three months or have specific health conditions that could complicate your participation. During the trial, participants will use the CGM devices to monitor their blood sugar levels and will likely have regular check-ins to discuss their experience. This study aims to make diabetes management easier and more effective, helping you better control your blood sugar levels after your hospital stay.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Non-pregnant adults, ages greater than or equal to 18 years, admitted to VUMC
• • Able to give informed consent
• • Hyperglycemia requiring insulin therapy including subcutaneous insulin injection or continuous subcutaneous insulin infusion (patient's own insulin pump) during hospitalization and at the time of discharge
• • POC glucose or venous glucose levels in the 24 hours prior to participation need to be 70-350 mg/dL
• • Need glucose readings greater than or equal to one time per day
• • Mental status and dexterity adequate to use Libre 3 Plus or Dexcom G7 sensors with Libre 3 or Dexcom G7 application on patient's smartphone
• Exclusion Criteria:
• • Currently using Libre 3 Plus or Dexcom G7 CGMS during hospitalization or have used Libre 3 Plus or Dexcom G7 CGMS in the past 3 months
• • Does not have smartphone compatible with Libre 3 App or Dexcom G7 App
• • Received chemotherapy during current hospitalization
• • Planning on major surgery within 10-15 days
• • Hemodialysis or peritoneal dialysis
• • Requiring vasopressors, intubation, sedation, or admission to an intensive care unit
• • Vitamin C use of more than 500 milligrams per day
• • Hydroxyurea use
• • Acetaminophen use of more than 4 grams per day or 1 gram every 6 hours
• • Significant pitting edema (3+ or greater) i.e. cirrhosis with ascites, congestive heart failure with edema, nephrotic syndrome, or signs of poor perfusion
• • Presentation in diabetic ketoacidosis or hyperosmotic nonketotic state
• • Skin allergy to adhesives